Established therapies and novel targets in the treatment of Parkinson’s disease

References

• Therapeutics of Parkinson’s Disease and Other Movement Disorders. Hallett M, Poewe W (Eds). Wiley-Blackwell, London, UK (2008).
   Google Scholar
• Schapira AHV. Neurobiology and treatment of Parkinson’s disease. Trends Pharmacol. Sci.30, 41–47 (2008).
   Google Scholar
• Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson’s disease. Mov. Disord.21, 1806–1823 (2006).
   PubMed Web of Science ®Google Scholar
• Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res.318, 121–134 (2004).
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med.351, 2498–2508 (2004).
   PubMed Web of Science ®Google Scholar
• Suchowersky O, Gronseth G, Perlmutter J et al. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Neurology66, 976–982 (2006).
   PubMed Web of Science ®Google Scholar
• Stocchi F. Optimizing levodopa therapy for the management of Parkinson’s disease. J. Neurol.252, 43–48 (2005).
   Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol.5, 677–687 (2006).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s disease. Mov. Disord.24, 541–550 (2009).
   PubMed Web of Science ®Google Scholar
• Stocchi F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Parkinsonism Relat. Disord.15(Suppl. 1), S9–S15 (2009).
   PubMed Web of Science ®Google Scholar
• Zubair M, Jackson MJ, Tayarani-Binazir K et al. The administration of entacapone prevents levodopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. Exp. Neurol.208, 177–184 (2007).
   PubMedGoogle Scholar
• Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson disease. JAMA284, 1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N. Engl. J. Med.342, 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Simuni T, Lyons KE, Pahwa R et al. Treatment of early Parkinson’s disease. Eur. Neurol.61, 193–205 (2009).
   Google Scholar
• Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr. Med. Res. Opin.24, 2883–2895 (2008).
   PubMed Web of Science ®Google Scholar
• Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology68, 272–276 (2007).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain125, 2058–2066 (2002).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Molinero A, Perez-Martinez DA, Catala A, Cabestany J, Yuste A. Treatment of Parkinson’s disease could be regulated by movement sensors: subcutaneous infusion of varying apomorphine doses according to the intensity of motor activity. Med. Hypotheses72, 430–433 (2009).
   Google Scholar
• Stewart A, Factor DO. Intermittent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology62, S12–S17 (2004)
   Google Scholar
• Jost W, Katrin K. Piribedil: first results of an observational study (PIR-001/K) investigating tolerability, effectiveness and prescribing practice of piribedil in Germany. Mov. Disord.24(Suppl. 1), S271 (2009).
   Google Scholar
• Elahi B, Sun X, Chen R. Effects of NMDA receptor antagonists on levodopa induced dyskinesia. Meta analysis of controlled clinical trials. Mov. Disord.24(Suppl. 1), S263 (2009).
   Web of Science ®Google Scholar
• Kuno SA, Uchida Y, Ogawa M. Long-term effects of amantadine for levodopa-induced dyskinesias and motor impairment in Parkinson’s disease: retrospective report. Mov. Disord.24(Suppl. 1), S267 (2009).
   Google Scholar
• Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology72, S1–S136 (2009)
   PubMed Web of Science ®Google Scholar
• Knoll J, Ecseri Z, Kelemen K, Nievel JG, Knoll B. [Phenylisopropylmethylpropinylamine (E250), a psychoenergetic with new spectrum of effect]. MTA V. Oszt. Közl.15, 231–239 (1964).
   Google Scholar
• Magyar K, Vizi ES, Ecseri Z, Knoll J. Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E250). Acta Physiol. Hung.32, 377–387 (1967).
   PubMedGoogle Scholar
• Birkmayer W, Knoll J, Riederer P. Improvement of life expectancy due to L-deprenyl addition to Madopar treatment in Parkinson’s disease: a long term study. J. Neural. Transm.113–127 (1985).
   Google Scholar
• Magyar K, Szende B. Deprenyl, a selective MAO-B inhibitor, with apoptotic and antiapoptotic properties. Neurotoxicology25, 233–242 (2004).
   PubMed Web of Science ®Google Scholar
• Magyar K, Pálfi M, Jenei V, Szöko É. Deprenyl: from chemical synthesis to neuroprotection. J. Neural. Transm.71(Suppl.), 143–156 (2006).
   Google Scholar
• Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology66, 1200–1206 (2006).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease. Mov. Disord.24, 564–573 (2009).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease, the TEMPO study. Arch. Neurol.59, 1937–1943 (2002).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson’s disease. Arch. Neurol.61, 561–566 (2004).
   PubMed Web of Science ®Google Scholar
• Olanow CW. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?. Neurology72, S59–S64 (2009).
   PubMedGoogle Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations, the PRESTO study. Arch. Neurol.62, 241–248 (2005).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel group trial. Lancet365, 947–954 (2005).
   PubMed Web of Science ®Google Scholar
• Giladi N, Rascol O, Brooks DJ et al. Rasagiline treatment can improve freezing of gait in advanced Parkinson’s disease; a prospective randomized, double-blind, placebo and entacapone controlled study. Neurology62(Suppl. 5), 329–330 (2004).
   Google Scholar
• Poewe W, Hauser R, Lang AE. Rasagiline 1mg/day provides benefits in the progression of non-motor symptoms in patients with early Parkinson’s disease: assessment with the revised MDS-UPDRS. Mov. Disord.24(Suppl. 1), S272 (2009).
   Google Scholar
• Grosset D, Taurah L, Burn DJ, MacMahon D, Forbes A, Turner K. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis. J. Neurol. Neurosurg. Psychiatry78, 465–469 (2007).
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Martin W, Suchowersky O et al. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology58, 11–17 (2002).
   PubMed Web of Science ®Google Scholar
• Fox MW, Ahlskog JE, Kelly PJ. Stereotactic ventrolateralis thalamotomy for medically refractory tremor in postlevodopa era Parkinson’s disease patients. J. Neurosurg.75, 723–730 (1991).
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano A, Montgomery E, Duff J, Tasker R, Hutchinson W. Posteroventral medial pallidotomy in advanced Parkinson’s disease. N. Engl. J. Med.337, 1036–1042 (1997)
   PubMed Web of Science ®Google Scholar
• Koller W, Pahwa R, Busenbark K et al. High frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol.42, 292–299 (1997)
   PubMed Web of Science ®Google Scholar
• Schupbach M, Gargiulo M, Welter ML et al. Stimulation of the subthalamic nucleus in Parkinson’s disease; a 5 year follow up. J. Neurol. Neurosurg. Psychiatry76, 1640–1644 (2005)
   PubMed Web of Science ®Google Scholar
• Plaha P, Ben-Shlomo Y, Patel NK, Gill SS. Stimulation of the caudal zone incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. Brain129, 1732–1747 (2006).
   PubMed Web of Science ®Google Scholar
• Stefani A, Lozano AM, Peppe A et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain130, 1596–1607 (2007).
   PubMed Web of Science ®Google Scholar
• Rothlind JC, Cockshott RW, Starr PA, Marks WJ Jr. Neuropsychological performance following staged bilateral pallidal or subthalamic nucleus deep brain stimulation for Parkinson’s disease. J. Int. Neuropsychol.13, 68–79 (2007).
   PubMed Web of Science ®Google Scholar
• Dass B, Olanow CW, Kordower J. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson’s disease. Neurology66(10 Suppl. 4), S89–S103 (2006)
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson’s disease. Trends Neurosci.19, 102–109 (1996).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Goetz CG, Kordower JH et al. A double blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol.54, 403–414 (2003)
   PubMed Web of Science ®Google Scholar
• Olanow CW, Gracies J-M, Goetz CG et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson’s disease: a double-blind video-based analysis. Mov. Disord.24, 336–343 (2009).
   PubMed Web of Science ®Google Scholar
• Stover NP, Bakay RA, Subramanian T et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch. Neurol.62, 1833–1837 (2005).
   PubMed Web of Science ®Google Scholar
• Dezawa M, Kanno H, Hoshino M et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J. Clin. Invest.113, 1701–1710 (2004).
   PubMed Web of Science ®Google Scholar
• Chang HY, Cotsarelis G. Turning skin into embryonic stem cells. Nat. Med.13, 783–784 (2007).
   PubMed Web of Science ®Google Scholar
• Bankiewicz KS, Porsayeth J, Eberling JL et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther.14, 564–570 (2006).
   PubMed Web of Science ®Google Scholar
• Kaplitt MG, Feigin A, Tang C et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, Phase I trial. Lancet369, 2097–2105 (2007)
   PubMed Web of Science ®Google Scholar
• Kordower JH, Herzog CD, Dass B et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann. Neurol.60, 706–715 (2006).
   PubMed Web of Science ®Google Scholar
• Marks WL, Verhagen Metman L, Starr P et al. Neurturin gene transfer for Parkinson’s disease: motor outcomes from the initial CERE-120 clinical trial. Mov. Disord.21(Suppl. 15), 1012 (2006).
   Google Scholar
• Simuni T, Lyons KE, Pahwa R et al. Treatment of early Parkinson’s disease. Eur. Neurol.61, 206–215 (2009).
   Google Scholar
• Weintraub D, Morales KH, Moberg PJ et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov. Disord.20, 1161–1169 (2005).
   PubMed Web of Science ®Google Scholar
• Lemke MR, Brecht HM, Koester J, Reichmann H: Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J. Neurol. Sci.248, 266–270 (2006).
   PubMed Web of Science ®Google Scholar
• Menza M, Dobkin RD, Marin H et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology72, 886–892 (2009).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov. Disord.20, 1255–1263 (2005)
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira HV. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol.8, 464–474 (2009).
   PubMed Web of Science ®Google Scholar
• Leroi J, Collins D, Marsh L. Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson’s disease: a review. J. Neurol. Sci.248, 104–114 (2006).
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A et al. Donazepil for dementia in Parkinson’s disease: a randomized, double blind crossover study. J. Neurol. Neurosurg. Psychiatry76, 934–939 (2005)
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Walker Z et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double blind, placebo controlled, multicentre trial. Lancet Neurol.8, 613–618 (2009)
   PubMed Web of Science ®Google Scholar
• Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J. Neurol. Neurosurg. Psychiatry76, 1636–1639 (2005).
   PubMed Web of Science ®Google Scholar
• Fox S, Brotchie J, Lang A. Non-dopaminergic treatments in development for Parkinson’s disease. Lancet Neurol.7, 927–938 (2008).
   PubMed Web of Science ®Google Scholar
• Simuni T, Lyons KE, Pahwa R et al. Treatment of early Parkinson’s disease. Eur. Neurol.61, 206–215 (2009).
   Google Scholar
• Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson’s disease: a review. Parkinsonism Relat. Disord.15, 81–87 (2009).
   PubMed Web of Science ®Google Scholar
• Shapira AH, Olanow CW. Neuroprotection in Parkinson’s disease: mysteries, myths and misconceptions. JAMA291, 358–364 (2004).
   Google Scholar
• Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr. Dis. Treat.4, 743–757 (2008).
   PubMedGoogle Scholar
• Shults CW, Oakes D, Kieburtz K et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol.59, 1541–1550 (2002).
   PubMed Web of Science ®Google Scholar
• Singer C, Papapetropoulos S, Gonzalez MA, Roberts EL, Lieberman A. Rimantadine in Parkinson’s disease patients experiencing peripheral adverse effects from amantadine: report of a case series. Mov. Disord.20, 873–877 (2005).
   PubMedGoogle Scholar
• Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN. Dextrometorphan improves levodopa-induced dyskinesias in Parkinson’s disease. Neurology51, 203–206 (1998)
   PubMedGoogle Scholar
• Picconi B, Centonze D, Hakansson K et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA induced dyskinesia. Nat. Neurosci.6, 501–506 (2003)
   PubMed Web of Science ®Google Scholar
• Merims D, Ziv I, Djaldetti R, Melamed E. Riluzole for levodopa-induced dyskinesias in advanced Parkinson’s disease. Lancet353, 1764–1765 (1999)
   PubMed Web of Science ®Google Scholar
• Rákóczi K, Klivényi P, Vécsei L. [Neuroprotection in Parkinson’s disease and other neurodegenerative disorders: experimental and clinical data]. Clin. Neurosci.62, 25–34 (2009).
   Google Scholar
• Németh H, Toldi J, Vécsei L. Kynurenines, Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical studies. J. Neurol. Trans.70, 285–304 (2006).
   Google Scholar
• Hartai Z, Klivényi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in plasma and in red blood cells in Parkinson’s disease. J. Neurol. Sci.239, 31–35 (2005).
   PubMed Web of Science ®Google Scholar
• Samadi P, Gregoire L, Rassoulpour A et al. Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys. Mov. Disord.20, 792–802 (2005).
   PubMed Web of Science ®Google Scholar
• Gregoire L, Rassoulpour A, Guidetti P et al. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav. Brain Res.186, 161–167 (2008).
   PubMed Web of Science ®Google Scholar
• Moroni F, Cozzi A, Carpendo R, Cipriani G, Veneroni O, Izzo E. Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus. Neuropharmacology48, 788–795 (2005).
   PubMed Web of Science ®Google Scholar
• Knyihar-Csillik E, Csillik B, Pakaski M et al. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. Neuroscience126, 899–914 (2004).
   PubMed Web of Science ®Google Scholar
• Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson’s disease. Trends. Neurosci.29, 647–654 (2006).
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Kuno S, Yamamoto M, Hasegawa K, Kondo T. Clinical efficacy of istradefylline (KW-6002) in the treatment of Parkinson’s disease: a randomized placebo-controlled study. Mov. Disord.24(Suppl. 1), S269– (2009).
   Google Scholar
• Caccia C, Maj R, Calabresi M et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology67(Suppl. 2), S18–S23 (2006).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Arnold G, Onofrj M et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology63, 746–748 (2004).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Grassini P et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology67(Suppl. 2), S24–S29 (2006).
   PubMed Web of Science ®Google Scholar
• Murata M, Kanazawa I. Long-term efficacy and safety of zonisamide on Parkinson’s disease: up to 9 years. Mov. Disord.24(Suppl. 1), S271– (2009).
   Google Scholar
• Lacivita E, Leopoldo M, Berardi F, Perrone R. 5-HT1A receptor, an old target for new therapeutic agents. Curr. Top. Med. Chem.8, 1024–1034 (2008).
   PubMed Web of Science ®Google Scholar
• Sage JI, Hauser RA, Cordon ME et al. Pilot study of the efficacy and safety of piclozotan in Parkinson’s disease patients with levodopa induced motor complications. Mov. Disord.24(Suppl. 1), S277 (2009).
   PubMed Web of Science ®Google Scholar
• Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson’s disease. Mov. Disord.19, 1183–1186 (2004).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson’s disease. Mov. Disord.22, 359–365 (2007).
   PubMed Web of Science ®Google Scholar
• Rascol O, Poewe W, Lees A et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS study. Arch. Neurol.65, 577–583 (2008).
   PubMed Web of Science ®Google Scholar
• Burke RE. Kinase signalling pathways: potential therapeutic targets in Parkinson’s disease. Future Neurol.2(1), 39–49 (2007).
   Google Scholar
• Simuni T, Martel A, Zadikoff C et al. Safety and tolerability of isradipine, a dihydropyridine calcium channel blocker, in patients with early Parkinson’s disease. Mov. Disord.23, 1629 (2008).
   Google Scholar